Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

NewLink Genetics

Status: Terminated

Conditions: Pancreatic Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT03165188

NLG0705

Details and patient eligibility

About

This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.

Enrollment: 29 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Receipt of at least one dose of algenpantucel-L within the past 15 years
• Signed consent